JP2017522903A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017522903A5 JP2017522903A5 JP2017517406A JP2017517406A JP2017522903A5 JP 2017522903 A5 JP2017522903 A5 JP 2017522903A5 JP 2017517406 A JP2017517406 A JP 2017517406A JP 2017517406 A JP2017517406 A JP 2017517406A JP 2017522903 A5 JP2017522903 A5 JP 2017522903A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- antibody
- antigen
- macromolecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 40
- 102000036639 antigens Human genes 0.000 claims 40
- 108091007433 antigens Proteins 0.000 claims 40
- 229920002521 macromolecule Polymers 0.000 claims 22
- 239000012634 fragment Substances 0.000 claims 21
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims 20
- 102000049284 human IL7R Human genes 0.000 claims 15
- 230000003278 mimic effect Effects 0.000 claims 15
- 150000001413 amino acids Chemical class 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 238000002054 transplantation Methods 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 208000023275 Autoimmune disease Diseases 0.000 claims 5
- 102100021592 Interleukin-7 Human genes 0.000 claims 5
- 108010002586 Interleukin-7 Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 239000004480 active ingredient Substances 0.000 claims 5
- 208000026935 allergic disease Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000027866 inflammatory disease Diseases 0.000 claims 5
- 208000023504 respiratory system disease Diseases 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 230000005764 inhibitory process Effects 0.000 claims 4
- 230000011664 signaling Effects 0.000 claims 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 3
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 3
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 claims 3
- 208000036142 Viral infection Diseases 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 230000001363 autoimmune Effects 0.000 claims 3
- 230000005784 autoimmunity Effects 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 108040006861 interleukin-7 receptor activity proteins Proteins 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 230000009385 viral infection Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 238000011284 combination treatment Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000002491 encephalomyelitis Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 230000035800 maturation Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 238000011084 recovery Methods 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 238000011269 treatment regimen Methods 0.000 claims 2
- 241000271566 Aves Species 0.000 claims 1
- 102100023698 C-C motif chemokine 17 Human genes 0.000 claims 1
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 1
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 claims 1
- 108010041012 Integrin alpha4 Proteins 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 102000001712 STAT5 Transcription Factor Human genes 0.000 claims 1
- 108010029477 STAT5 Transcription Factor Proteins 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 125000003636 chemical group Chemical group 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 230000033581 fucosylation Effects 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 108010021315 integrin beta7 Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021128846A JP2021184731A (ja) | 2014-06-10 | 2021-08-05 | Ｃｄ１２７に対する抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462010117P | 2014-06-10 | 2014-06-10 | |
| US62/010,117 | 2014-06-10 | ||
| EP15305078.6 | 2015-01-23 | ||
| EP15305078.6A EP2955196A1 (en) | 2014-06-10 | 2015-01-23 | Antibodies directed against CD127 |
| PCT/EP2015/062993 WO2015189302A1 (en) | 2014-06-10 | 2015-06-10 | Antibodies directed against cd127 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021128846A Division JP2021184731A (ja) | 2014-06-10 | 2021-08-05 | Ｃｄ１２７に対する抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017522903A JP2017522903A (ja) | 2017-08-17 |
| JP2017522903A5 true JP2017522903A5 (enExample) | 2018-07-19 |
| JP7324565B2 JP7324565B2 (ja) | 2023-08-10 |
Family
ID=52434718
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017517406A Active JP7324565B2 (ja) | 2014-06-10 | 2015-06-10 | Ｃｄ１２７に対する抗体 |
| JP2021128846A Pending JP2021184731A (ja) | 2014-06-10 | 2021-08-05 | Ｃｄ１２７に対する抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021128846A Pending JP2021184731A (ja) | 2014-06-10 | 2021-08-05 | Ｃｄ１２７に対する抗体 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10428152B2 (enExample) |
| EP (2) | EP2955196A1 (enExample) |
| JP (2) | JP7324565B2 (enExample) |
| KR (1) | KR102612930B1 (enExample) |
| CN (1) | CN106715471B (enExample) |
| AP (1) | AP2016009599A0 (enExample) |
| AU (1) | AU2015273532C1 (enExample) |
| BR (1) | BR112016028755B1 (enExample) |
| CA (1) | CA2950823A1 (enExample) |
| CL (1) | CL2016003172A1 (enExample) |
| CR (1) | CR20160576A (enExample) |
| EA (1) | EA039303B1 (enExample) |
| HK (1) | HK1231487A1 (enExample) |
| IL (1) | IL249449B (enExample) |
| MA (1) | MA40202A (enExample) |
| MX (1) | MX376066B (enExample) |
| MY (1) | MY190889A (enExample) |
| NZ (1) | NZ726932A (enExample) |
| PE (1) | PE20170324A1 (enExample) |
| PH (1) | PH12016502445A1 (enExample) |
| RU (1) | RU2734076C2 (enExample) |
| SA (1) | SA516380455B1 (enExample) |
| SG (1) | SG11201610036PA (enExample) |
| TN (1) | TN2016000528A1 (enExample) |
| UA (1) | UA125366C2 (enExample) |
| WO (1) | WO2015189302A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013124474A2 (en) | 2012-02-23 | 2013-08-29 | Stage Cell Therapeutics Gmbh | Chromatographic isolation of cells and other complex biological materials |
| EP2955196A1 (en) * | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
| WO2016156468A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptides |
| CN107427577A (zh) | 2015-03-31 | 2017-12-01 | 韦斯夸尔德有限公司 | 具有蛋白酶可切割接头的肽构建体 |
| IL258844B2 (en) | 2015-10-22 | 2024-03-01 | Juno Therapeutics Gmbh | Methods for culturing cells and kits and apparatus for same |
| WO2017125578A1 (en) | 2016-01-21 | 2017-07-27 | Vhsquared Limited | Polypeptides |
| RS59223B1 (sr) * | 2016-02-29 | 2019-10-31 | Ose Immunotherapeutics | Ne-antagonistička antitela usmerena protiv alfa lanca ekstracelularnog domena il7 receptora i njihova upotreba u lečenju kancera |
| PE20191152A1 (es) | 2016-12-09 | 2019-09-05 | Ose Immunotherapeutics | Anticuerpos y polipeptidos dirigidos contra cd127 |
| EP3676292A1 (en) * | 2017-08-29 | 2020-07-08 | OSE Immunotherapeutics | Method and preparation for sorting out t effector cells using anti-cd127 antibodies for applications in cell therapy |
| CN110117325B (zh) * | 2018-03-09 | 2023-06-20 | 重庆市畜牧科学院 | 一种猪cd127多肽及其编码基因和应用 |
| KR20230128134A (ko) | 2019-01-22 | 2023-09-01 | 브리스톨-마이어스 스큅 컴퍼니 | Il-7r 알파 서브유닛에 대한 항체 및 이의 용도 |
| IL288024B2 (en) | 2019-05-14 | 2025-12-01 | Provention Bio Inc | Methods and compositions for preventing type |
| MX2021015762A (es) | 2019-06-21 | 2022-04-18 | Sorriso Pharmaceuticals Inc | Composiciones. |
| MX2021015761A (es) | 2019-06-21 | 2022-04-18 | Sorriso Pharmaceuticals Inc | Polipeptidos. |
| AU2020296979A1 (en) | 2019-06-21 | 2022-02-24 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
| CN110894237B (zh) * | 2019-12-05 | 2021-08-03 | 山东省分析测试中心 | 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用 |
| EP4142777A4 (en) * | 2020-04-27 | 2024-06-12 | Memorial Sloan-Kettering Cancer Center | CHIMERIC ANTIGEN RECEPTORS DIRECTED TO CD127 AND USE THEREOF |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| US20220389104A1 (en) * | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
| CA3250546A1 (en) | 2022-05-30 | 2023-12-07 | Ose Immunotherapeutics | IL7R MODULATOR ACTIVITY BIOMARKERS |
| CN115925955B (zh) * | 2022-12-30 | 2025-09-26 | 浙江正熙生物技术有限公司 | 一种抗cd127抗体及其制备方法和应用 |
| EP4646274A1 (en) | 2023-01-06 | 2025-11-12 | Twain Therapeutics Pte. Ltd. | Antigen-binding molecules |
| EP4455308A1 (en) | 2023-04-24 | 2024-10-30 | Les Laboratoires Servier | Il-7r gene signatures |
| CN121666232A (zh) | 2023-05-31 | 2026-03-13 | 开普斯坦治疗公司 | 脂质纳米颗粒制剂和组合物 |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025089399A1 (ja) * | 2023-10-26 | 2025-05-01 | 国立研究開発法人国立がん研究センター | インターロイキン７受容体（ｉｌ－７ｒ）に対する抗体および当該抗体を含む抗体薬物コンジュゲート（ａｄｃ） |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025202213A1 (en) | 2024-03-26 | 2025-10-02 | Institut National de la Santé et de la Recherche Médicale | Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| CN118638236B (zh) * | 2024-07-09 | 2025-03-14 | 武汉爱博泰克生物科技有限公司 | 抗人cd127蛋白的抗体、抗体偶联物及其应用 |
| WO2026022216A1 (en) | 2024-07-23 | 2026-01-29 | Ose Immunotherapeutics | Uses of anti-cd127 antibodies in the treatment of inflammatory bowel diseases |
| WO2026033132A1 (en) | 2024-08-09 | 2026-02-12 | Twain Therapeutics Pte. Ltd. | Antigen-binding molecules |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| AU2007266450A1 (en) | 2006-05-31 | 2007-12-06 | The Regents Of The University Of California | CD127 expression inversely correlates with FoxP3 and suppressive function of CD4+ Tregs |
| EP1930342B1 (en) | 2006-12-04 | 2012-01-25 | Institut Pasteur | OB-fold used as scaffold for engineering new specific binders |
| UY32038A (es) | 2008-08-08 | 2010-03-26 | Glaxo Wellcome Mfg Pte Ltd | Inmunoblobulinas anti-cd127 y sus usos |
| WO2010085643A1 (en) | 2009-01-22 | 2010-07-29 | University Of Miami | Targeting il-7 signaling as a therapy for multiple sclerosis and other il-7 signaling dependent disorders |
| US8940303B2 (en) * | 2010-01-28 | 2015-01-27 | Glaxo Group Limited | CD127 binding proteins |
| US8298535B2 (en) | 2010-02-24 | 2012-10-30 | Rinat Neuroscience Corp. | Anti-IL-7 receptor antibodies |
| EP2583980A1 (en) | 2011-10-19 | 2013-04-24 | Effimune | Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates |
| EP2955196A1 (en) * | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
| RS59223B1 (sr) | 2016-02-29 | 2019-10-31 | Ose Immunotherapeutics | Ne-antagonistička antitela usmerena protiv alfa lanca ekstracelularnog domena il7 receptora i njihova upotreba u lečenju kancera |
-
2015
- 2015-01-23 EP EP15305078.6A patent/EP2955196A1/en not_active Withdrawn
- 2015-06-10 AP AP2016009599A patent/AP2016009599A0/en unknown
- 2015-06-10 MY MYPI2016002094A patent/MY190889A/en unknown
- 2015-06-10 MA MA040202A patent/MA40202A/fr unknown
- 2015-06-10 CR CR20160576A patent/CR20160576A/es unknown
- 2015-06-10 SG SG11201610036PA patent/SG11201610036PA/en unknown
- 2015-06-10 AU AU2015273532A patent/AU2015273532C1/en active Active
- 2015-06-10 UA UAA201613258A patent/UA125366C2/uk unknown
- 2015-06-10 MX MX2016016236A patent/MX376066B/es active IP Right Grant
- 2015-06-10 PE PE2016002699A patent/PE20170324A1/es unknown
- 2015-06-10 CA CA2950823A patent/CA2950823A1/en active Pending
- 2015-06-10 WO PCT/EP2015/062993 patent/WO2015189302A1/en not_active Ceased
- 2015-06-10 KR KR1020177000724A patent/KR102612930B1/ko active Active
- 2015-06-10 TN TN2016000528A patent/TN2016000528A1/en unknown
- 2015-06-10 EA EA201692460A patent/EA039303B1/ru unknown
- 2015-06-10 EP EP15727989.4A patent/EP3155014A1/en active Pending
- 2015-06-10 CN CN201580043066.1A patent/CN106715471B/zh active Active
- 2015-06-10 NZ NZ726932A patent/NZ726932A/en unknown
- 2015-06-10 RU RU2016151265A patent/RU2734076C2/ru active
- 2015-06-10 BR BR112016028755-0A patent/BR112016028755B1/pt active IP Right Grant
- 2015-06-10 HK HK17104912.8A patent/HK1231487A1/zh unknown
- 2015-06-10 US US15/317,355 patent/US10428152B2/en active Active
- 2015-06-10 JP JP2017517406A patent/JP7324565B2/ja active Active
-
2016
- 2016-12-06 PH PH12016502445A patent/PH12016502445A1/en unknown
- 2016-12-07 IL IL249449A patent/IL249449B/en active IP Right Grant
- 2016-12-08 SA SA516380455A patent/SA516380455B1/ar unknown
- 2016-12-09 CL CL2016003172A patent/CL2016003172A1/es unknown
-
2019
- 2019-08-05 US US16/532,000 patent/US11440964B2/en active Active
-
2021
- 2021-08-05 JP JP2021128846A patent/JP2021184731A/ja active Pending
-
2022
- 2022-09-09 US US17/941,885 patent/US12371502B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017522903A5 (enExample) | ||
| JP2021184731A5 (enExample) | ||
| RU2016151265A (ru) | Антитела, направленные на cd127 | |
| JP6907124B2 (ja) | Ｃｄｈ３及びｃｄ３に対する二重特異性抗体構築物 | |
| AU2018261951B2 (en) | Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration | |
| JP6879998B2 (ja) | Ｃｄ７０及びｃｄ３に対する抗体構築物 | |
| JP6606505B2 (ja) | 抗ＳＩＲＰα抗体および二重特異性マクロファージ増強抗体 | |
| US9802995B2 (en) | Antibody multimerization technologies | |
| CN108271376B (zh) | 结合dll3和cd3的双特异性抗体构建体 | |
| WO2021063330A1 (zh) | 靶向cd3的抗体、双特异性抗体及其用途 | |
| TW201833141A (zh) | 抗b7-h3抗體、其抗原結合片段及其醫藥用途 | |
| JP2018537421A5 (enExample) | ||
| EA039594B1 (ru) | Биспецифические конструкции антител к bcma и cd3, вовлекающие т-клетки | |
| JP2016511277A5 (enExample) | ||
| JP2018527909A (ja) | Ｆｌｔ３及びｃｄ３に対する抗体構築物 | |
| JP2014524733A5 (enExample) | ||
| JP2011509245A5 (enExample) | ||
| TW201716441A (zh) | Ｅｇｆｒｖｉｉｉ及ｃｄ３抗體構築體 | |
| JP2018530996A6 (ja) | Ｃｄ７０及びｃｄ３に対する抗体構築物 | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| JP2018527919A5 (enExample) | ||
| JP2017519501A5 (enExample) | ||
| JP2020504759A (ja) | Ｓ．ａｕｒｅｕｓ溶血素ａ毒素に対するヒト抗体 | |
| JP2019521647A5 (enExample) | ||
| JP2021509274A (ja) | モノクローナル抗体およびその使用法 |